U.S. Markets open in 5 hrs 7 mins

RMB Mendon Financial Services Fund Class A (RMBKX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
Add to watchlist
54.41+0.37 (+0.68%)
At close: 8:01PM EDT
Full screen
Previous Close54.04
YTD Return33.66%
Expense Ratio (net)1.28%
Last Cap Gain0.00
Morningstar Rating★★★★★
Morningstar Risk RatingAbove Average
Sustainability Rating
Net Assets233.95M
Beta (5Y Monthly)1.33
5y Average ReturnN/A
Holdings Turnover27.00%
Last Dividend0.00
Average for CategoryN/A
Inception DateJun 07, 1999
  • AGTC to Present at Upcoming Investor Conferences

    AGTC to Present at Upcoming Investor Conferences

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in the following virtual investor conferences: H.C. Wainwright Global Life Sciences Conference ‎(March 9-10, 2021)A fireside chat with Sue Washer, President & Chief Executive Officer, will be available to view on-demand beginning Tuesday, March 9, 2021 at 7:00 a.m. ET through the entirety of the conference. 33rd Annual ROTH Conference (March 15-17, 2021)Ms. Washer and Mark Shearman, Chief Scientific Officer, will participate in a fireside chat at 1:00 p.m. ET on Monday, March 15, 2021. Audio webcasts of the presentation at the H.C. Wainwright and ROTH conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the events. About AGTCAGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. IR/PR CONTACTS: David Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768 or (646) 871-8485david.carey@finnpartners.com or glenn.silver@finnpartners.com Corporate Contacts:Bill SullivanChief Financial OfficerApplied Genetic Technologies CorporationT: (617) 843-5728 bsullivan@agtc.com Stephen PotterChief Business OfficerApplied Genetic Technologies CorporationT: (617) 413-2754spotter@agtc.com